

Is Elevated Gastric Tissue NOX2 Associated with Lymphoma of Mucosa-Associated Lymphoid Tissue?

Emilie Bessède, Christiane Copie-Bergman, Philippe Lehours, Michael Levy, Karen Leroy, Maryse Baia, Audrey Riou, Francis Mégraud, Jean-Charles Delchier, Nathalie Salles

► **To cite this version:**

Emilie Bessède, Christiane Copie-Bergman, Philippe Lehours, Michael Levy, Karen Leroy, et al.. Is Elevated Gastric Tissue NOX2 Associated with Lymphoma of Mucosa-Associated Lymphoid Tissue?. *Antioxidants and Redox Signaling*, Mary Ann Liebert, 2012, 16 (11), pp.1205-11. <10.1089/ars.2011.4494>. <inserm-00696815>

HAL Id: inserm-00696815

<http://www.hal.inserm.fr/inserm-00696815>

Submitted on 14 May 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Table 1. Clinical and molecular features of the 39 patients with primary gastric MALT lymphoma and 43 patients with gastritis (Control group).

	MALT lymphoma	Control group
Number of patients	39	43
Age at diagnosis	57.5	56
median age (range)	24-80	23-92
Men/women	23/16	20/23
Follow-up since diagnosis		
Median (range)	3 yrs [0-20yrs]	0
<i>H. pylori</i>-positive/ <i>H. pylori</i>-negative	19/20	17 /26
Extent of the disease		
Stage IE*/IIIE°/IV** (n)	23/9/7	–
Molecular status at diagnosis		
Detectable t(11;18), n	17	0
Sydney score at diagnosis		
Activity ≥ 2	4 (10%)	10 (23%)
Inflammation ≥ 2	13 (33%)	26 (60%)
Atrophy ≥ 2	5 (12,8%)	6 (14%)
Intestinal metaplasia ≥ 2	3 (7%)	2 (4%)
*disease limited to the stomach		
° perigastric lymph nodes on endoscopic ultra sound		
** medullar and/or pulmonary involvement		

Table 2. Expression of NOX2 and NOX5 in different biopsies according to the Updated Sydney system.

Sydney score (N = number of biopsies)	GML=39		Sydney score (N = number of biopsies)	Control group =43	
	NOX5 mean	NOX2 mean		NOX5 mean	NOX2 mean
activity = 0 (N=26)	0.00069	0.42697	activity = 0 (N=27)	0.00229	0.11760
activity = 1 (N=9)	0.00040	0,14821	activity = 1 (N=6)	0.00269	0.12649
activity = 2 (N=2)	0.00012	0,12849	activity = 2 (N=4)	0.00056	0.07035
activity = 3 (N=2)	0.00045	0,19357	activity = 3 (N=6)	0.00027	0.03783
inflammation = 0 (N=1)	0.00386	4,40762	inflammation = 0 (N=2)	0.00024	0.04669
inflammation = 1 (N=25)	0.00055	0,25169	inflammation = 1 (N=15)	0.00315	0.11444
inflammation = 2 (N=12)	0.00035	0,18026	inflammation = 2 (N=22)	0.00152	0.10853
inflammation = 3 (N=1)	0.00016	0,08105	inflammation = 3 (N=4)	0.00020	0.06120
atrophy = 0 (N=28)	0.00055	0,36885	atrophy = 0 (N=29)	0.00186	0.11647
atrophy = 1 (N=6)	0.00085	0,28605	atrophy = 1 (N=8)	0.00328	0.11401
atrophy = 2 (N=5)	0.00034	0,18000	atrophy = 2 (N=4)	0.00029	0.01942
atrophy = 3 (N=0)	-	-	atrophy = 3 (N=2)	0.00020	0.03762
intestinal metaplasia = 0 (N=34)	0.00061	0,36438	intestinal metaplasia = 0 (N=37)	0.00218	0.11400
intestinal metaplasia = 1(N=2)	0.00041	0,05450	intestinal metaplasia = 1 (N=4)	0.00021	0.04506
intestinal metaplasia = 2 (N=2)	0.00020	0,15561	intestinal metaplasia = 2 (N=2)	0.00019	0.02215
intestinal metaplasia = 3 (N=1)	0.00009	0,13490	intestinal metaplasia = 3 (N=0)	-	-

